INTENSIFIED TB CASE FINDING

Similar documents
Six I s HIV/TB Communication and Advocacy Toolkit

Targeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease

Research Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012

Latent tuberculosis infection

Intensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010

Diagnosis of tuberculosis

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Tuberculosis Tools: A Clinical Update

The New WHO guidelines on intensified TB case finding and Isoniazid preventive therapy and operational considerations

Northwestern Polytechnic University

Self-Study Modules on Tuberculosis

Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

Report on WHO Policy Statements

TB: A Supplement to GP CLINICS

Peggy Leslie-Smith, RN

Diagnosis of tuberculosis in children

TOG The Way Forward

TB: A Supplement to GP CLINICS

Nguyen Van Hung (NTP, Viet Nam)

Tuberculosis Populations at Risk

Ongoing Research on LTBI and Research priorities in India

Tuberculosis 6/7/2018. Objectives. What is Tuberculosis?

Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it

Dr Francis Ogaro MTRH ELDORET

CHAPTER 3: DEFINITION OF TERMS

Frances Morgan, PhD October 21, Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS

What Is New in Combination TB Prevention? Lisa J. Nelson Treatment and Care (TAC) Team HIV Department WHO HQ

Fundamentals of Tuberculosis (TB)

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

CHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

TB in the Patient with HIV

Kenya Perspectives. Post-2015 Development Agenda. Tuberculosis

Clinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis

How best to structure a laboratory network with new technologies

Tuberculosis (TB) Fundamentals for School Nurses

TB the basics. (Dr) Margaret (DHA) and John (INZ)

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016

of clinical laboratory diagnosis in Extra-pulmonary Tuberculosis

Diagnosis and Medical Management of Latent TB Infection

AN ACTIVIST S GUIDE TO. Tuberculosis Diagnostic Tools

Diagnostic challenges of active childhood TB in Tanzania. Michala Vaaben Rose, MD, Ph.D Department of Infectious Diseases, Hvidovre

Diagnosis Latent Tuberculosis. Disclosures. Case

Tuberculosis. New TB diagnostics. New drugs.new vaccines. Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012

Xpert MTB/RIF Training. Indira Soundiram 2012

Disclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None

TB Screening Guidelines for Transitional Care Unit

Cost-effectiveness of ART and the Three I s for HIV/TB to prevent tuberculosis

CULTURE OR PCR WHAT IS

LATENT TUBERCULOSIS. Robert F. Tyree, MD

Core Curriculum on Tuberculosis: What the Clinician Should Know

Ken Jost, BA, has the following disclosures to make:

Stop TB Poster (laminated copies are available from TB Control: )

TB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE)

Primary Care and TB Control Dr Helen Booth Consultant Thoracic Physician, UCLH Clinical Lead, Integrated TB NCL-Service

Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast

Detection and Treatment of Tuberculosis in Correctional Facilities: Opportunities and Challenges

Tuberculosis What you need to know. James Zoretic M.D., M.P.H. Regions 2 and 3 Director

Chapter 4 Diagnosis of Tuberculosis Disease

New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents

Xpert MTB/Rif What place for TB diagnosis in MSF projects? Francis Varaine, MSF Geneva, 29/11/10

Tuberculosis Facts. TB is not spread by: Sharing food and drink Shaking someone s hand Touching bed lines or toilet seats

(a) Infection control program. The facility must establish an infection control program under which it--

These recommendations will remain in effect until the national shortage of PPD solution has abated.

TUBERCULOSIS. Pathogenesis and Transmission

Laboratory Diagnosis of Tuberculosis: State-of-the-art

New Tuberculosis Guidelines. Jason Stout, MD, MHS

Management of Pediatric Tuberculosis in New Jersey

Approaches to LTBI Diagnosis

Standard Diagnostic Procedure for Tuberculosis: A Review

Programmatic management of latent TB infection: Global perspective and updates. Haileyesus Getahun, MD, MPH, PhD.

Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf

Urinary TB diagnostics in HIV

2017/2018 Annual Volunteer Tuberculosis Notice

CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]

Latent TB, TB and the Role of the Health Department

Latent Tuberculosis Best Practices

Communicable Disease Control Manual Chapter 4: Tuberculosis

Identifying TB co-infection : new approaches?

New Standards for an Old Disease:

TB Laboratory for Nurses

Programmatic management of LTBI : a two pronged approach for ending the TB epidemic. Haileyesus Getahun Global TB Programme WHO/HQ

Contact Follow-Up and Treatment of LTBI in Households of Infectious Cases in Pakistan

IPT IMPLEMENTATION- SWAZILAND EXPERIENCE

Implementation and scale-up of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB. Global Consultation

New NICE guideline updates recommendations for diagnosing latent tuberculosis

Testing for TB. Bart Van Berckelaer Territory Manager Benelux. Subtitle

CDC IMMIGRATION REQUIREMENTS:

Let s Talk TB. A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Xpert MTB/RIF use for TB diagnosis in TB suspects with no significant risk of drug resistance or HIV infection. Results of Group Work

Questions and Answers About

The Lancet Infectious Diseases

Rapid PCR TB Testing Results in 68.5% Reduction in Unnecessary Isolation Days in Smear Positive Patients.

TB infection control: overview and importance

Introduction. Diagnosis of extrapulmonaryand paediatric tuberculosis. Extrapulmonary tuberculosis EPTB SASCM WORKSHOP 2014/05/24

Making the Diagnosis of Tuberculosis

Childhood Tuberculosis Some Basic Issues. Jeffrey R. Starke, M.D. Baylor College of Medicine

HIV Clinicians Society Conference TB/HIV Treatment Cascade

Transcription:

INTENSIFIED TB CASE FINDING My friends call me Intensified Case Finding (ICF) I undertake regularly screening all people with, or at high risk of HIV, for symptoms of TB in health care facilities, communities as well as in homes. This is an important task because once we identity people who present with these signs and/ or symptoms, these friends are promptly diagnosed and immediately initiated on treatment. How do I go about my investigations keep reading and learn more! 16

09 What is Intensified Case Finding (ICF) for TB? Intensified Case Finding (ICF) for TB means regularly screening all people with, or at high risk of HIV, for the symptoms of TB, followed promptly with diagnosis and treatment, and then doing the same for household contacts. Current cough Active case finding and the provision of treatment to infected individuals is beneficial because: Active TB disease, if left untreated kills more than 50% of people infected. TB treatment also reduces the spread of infection; a person on TB treatment for at least 2 weeks can no longer spread TB to others. Screening for TB should be taking place both in health facilities, when people first seek HIV services and in other congregate settings (mines, prisons, schools, churches, and the home); in particular amongst people living with HIV. 10 How often should people living with HIV be screened for TB? Night Sweats People living with HIV should be screened for TB at every clinic or home visit, regardless of whether they have received or are receiving IPT or ART. 11 What is the WHO recommended screening algorithm for ruling out active TB, including extrapulmonary TB in people living with HIV? 18 As recommended by the WHO, all people living with HIV should be regularly screened for TB at every visit using a clinical algorithm whenever they are receiving care. At the minimum PHIV should be screened for common TB signs and symptoms for all types of TB disease. The WHO recommended screening algorithm for adults and adolescents living with HIV include a set of four symptoms: Current cough Fever Night sweats Weight loss The WHO recommends that adults and adolescents living with HIV who do not have any of these four symptoms are unlikely to have active TB and should be offered IPT. However, if any of these four symptoms are present, it may indicate the presence of active tuberculosis and the patient should be further evaluated for TB and other diseases. high temperature Weight Loss 18 DAl-Orainey IO. Diagnosis of latent tuberculosis: Can we do better? Ann Thorac Med, 2009; 4:5-9 17

12 What diagnostic tests exist to detect latent tuberculosis infection and confirm active TB disease? 19 DIAGNOSTIC TEST DIS Tubercilin Skin Test (TST) Small HOW amount DOES of IT TB WORK protein injected into the skin. If a person is infected with TB then a firm red bump will develop on the skin within 48-72 hours. An induration of 5 or more millimeters is considered positive in: HIV-infected persons A recent contact of a person with TB disease An induration of 15 or more millimeters is considered positive in any person, including persons with no known risk factors for TB. However, targeted skin testing programs should only be conducted among high-risk groups 20 Allows detection of latent TB. Inaccurate positive results for patients who received BCG vaccine or exposed to a different mycobacteria Inaccurate negative results in people living with HIV, people with poor nutrition and those with disseminated TB. Difficult to administer and interpret, costly, and has to be stored in cool temperatures. Patient has to return after 2 days to interpret results, which causes loss to follow up. Chest X-rays TB creates cavities in the lungs that may be visible through x-rays. Addition of abnormal chest radiographic findings to the four symptom based rule increases accuracy of diagnosis Increased cost and work load Requires qualified staff Only useful for detecting pulmonary TB, which is less common in PLHIV 19 UNITAID, Tuberculosis Diagnostic Technology Landscape, 2012, Available at http://www.stoptb.org/wg/new_diagnostics/ assets/documents/unitaid-tuberculosis-landscape_2012.pdf 20 Centers for Disease Control and Prevention (CDC), Tuberculin Skin Testing, 2016, Available at http://www.cdc.gov/tb/ publications/factsheets/testing/skintesting.htm 18

DIAGNOSTIC TEST DIS Smear microscopy Biological samples (normally sputum) are dyed, placed on a glass slide and looked at under a microscope. The dye makes mycobacteria easier to see, allowing for a diagnosis to be made. 21 Cost-effective test. 22 Improvements in automated smear testing and light-emitting diodes (LED) 23 microscopy have the potential to greatly improve testing due to improved accuracy in testing TB in PLHIV and less workload. 24 Poor results in identifying TB if co-infected with HIV since 24%-61% of PLHIV with TB are smear negative Further developments are needed regarding capitalising on smear microscopy. The process remains relatively unchanged 25 Light-emitting diodes fluorescence microscopy (LED) Smears are stained with a fluorescent dye and examined under a microscope LED-FM could reduce the high workload required for smear microscopy as it is automated. With LED-FM, smears can be examined in 90 seconds- a quarter of the time it takes to examine samples using smear microscopy. 26 Higher sensitivity but lower specificity than smear microscopy. Therefore the method should detect more cases of TB but may also treat people who do not have TB. There are also electricity and laboratory requirements. 21 Smart, T, Background on smear microscopy in TB diagnosis, 2012, Available at: http://www.aidsmap.com/background-onsmear-microscopy-in-tb-diagnosis/page/1426650/ 22 If a patient tests smear-positive transmitting TB is very likely. High TB transmission occurs in facilities with poor infection control. Thus (smear microscopy testing) has the potential to curtail infection. 23 LED: Fluorescent Light Emitting Diode. LED microscope lamp is inexpensive when compared to the mercury vapor or halogen lamp used in regular fluorescent microscopy and has a life span of more than 10,000-50,000 hours (http://www. finddiagnostics.org/programs/tb/find_activities/led_microscopy.html_ 24 Minion J. et al, Comparison of LED and Conventional Fluorescence Microscopy for Detection of Acid Fast Bacilli in a Low- Incidence Setting, 2011, PLoS ONE 6(7): e22495. doi:10.1371/journal.pone.0022495 25 Smart, T, Determine LAM urine antigen TB test is highly cost-effective for use in hospitalised people living with HIV, 2012, Available at http://www.aidsmap.com/determine-lam-urine-antigen-tb-test-is-highly-cost-effective-for-use-in-hospitalisedpeople-living-with-hiv/page/2455261/ 26 Cuevas LE, Al-Sonboli N, Lawson L, Yassin MA, Arbide I, Al-Aghbari N, et al, LED Fluorescence Microscopy for the Diagnosis of Pulmonary Tuberculosis: A Multi-Country Cross-Sectional Evaluation, 2011, PLoS Med 8(7): e1001057. doi:10.1371/journal.pmed Retrieved from http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001057 19

DIAGNOSTIC TEST Light-emitting diodes fluorescence microscopy (LEDFM) (continued) Compared to conventional mercury fluorescence microscopes, LED microscopes are less expensive and have lower maintenance requirements. The diodes are very durable, do not require warm-up time, and do not contain toxic products. Importantly, they are reported to perform equally well without a darkroom. These qualities make them attractive for use in low- and middle-income countries. 27 DIAGNOSTIC TEST DIS Line Probe Assay Is a molecular diagnostic (LPA) test which amplifies the DNA of TB. If TB is present in a sample, it will amplify the TB DNA and yield a positive result. The test detects both TB bacteria and TB strains that are resistant to Isoniazid and Rifampicin. Hence the test diagnoses MDR-TB. 28 LPA testing can be used with sputum samples and culture isolates, and when used with sputum samples, LPA can deliver results within 2 days, rather than 6 weeks. Both INH and Rif resistance can be detected by this test. A new version can be used for all samples irrespective of smear result (both smear positive and smear negative). A 2nd-line line probe assay also in development. 29 Instrument requires specialised facilities and access to a stable electricity supply, and are best utilised on smear positive TB cases. However, the new version of this diagnostic test is expensive. Xpert MTB/RIF Xpert is a molecular diagnostic test, which amplifies the TB DNA within a sample. Sample (unprocessed sputum or sediment from concentrated specimen) is incubated for 15 minutes in a tube. Diluted sample is put into cartridge with a pipette, which is then inserted for the test. It is used for the diagnosis of pulmonary TB, by use of sputum samples. The sputum samples require minimal manipulation and results are available in 2 hours. There are ongoing studies showing varying sensitivities for diagnosis of EPTB The test detects TB and TB strains with rifampicin resistance. Suitable for individuals at risk for MDR-TB and smear negative specimen from PLHIV as it has better sensitivity than smear microscopy to detect TB in PLHIV. Xpert is the fastest molecular TB diagnostic test. Not cost effective cannot be used in all types of facilities (e.g. stable electricity and air conditioning are needed). Costs $10 per cartridge test yet studies in South Africa show costs such as shipping etc increase this to $25. 30 Only detects Rifresistance and not INH resistance, and hence confirmatory testing is needed. Staff training required to ensure treatment initiation and testing is on same day. Sample processing of at least 15 minutes is required; although there is minimal handling of sample. 27 Smart, T. Determine LAM urine antigen TB test is highly cost-effective for use in hospitalised people living with HIV. 20 28 Minion J et al. Comparison of LED and Conventional Fluorescence Microscopy for Detection of Acid Fast Bacilli in a Low- Incidence Setting, 2011, Available at http://www.plosone.org/article/info:doi/10.1371/journal.pone.0022495 29 Molecular Line Probe for Assays for Rapid Screening of Patients at Risk of Multidrug-Resistant Tuberculosis (MDR-TB), 2008, World Health Organisation, Available at http://www.who.int/tb/features_archive/expert_group_report_june08.pdf

DIAGNOSTIC TEST DIS Determine TB-LAM assay Urine antigen is tested from the urine cell wall. LAM is a protein found in the outer cell wall of TB. The test requires no processing and is preferred for high burden setting in combination with other tests. It is used as rule in test to detect active TB. It is a molecular diagnostic (LPA) test which amplifies the DNA of TB. If TB is present in a sample, it will amplify the TB DNA and yield a positive result. The test detects both TB bacteria and TBs Relatively cost-effective at $2.50-3.50/test. 31 Easy sample processing required. Easy storage conditions for diagnostic kit. Easy readability of results. Handling urine decreases the risk of infection that can occur with blood and sputum. Urine is easier to obtain than sputum; which is especially useful for people coinfected with HIV and extrapulmonary TB who have difficulty producing sputum. Rapid diagnostic test; only takes 25 minutes. This is a point of care test which is suitable for basic health facilities (in limited resource settings). Test is not sensitive. It is most sensitive (57%) in PLHIV with CD4 counts below 100, used in combination with other tests for confirmation. 32 WHO has not yet endorsed this test although there is much evidence on accuracy of the test. 31 Dheda. K, TB diagnostic tests Why and when to use them? 2011, Available at http://old.criticalcare.org.za/images/ presentations/keertan%20dheda%20(3).pdf 32 Fluorescent light-emitting diode (LED) microscopy for diagnosis of tuberculosis, Policy Statement, 2011. World Health Organisation, Geneva, Switzerland, Avaialble at http://apps.who.int/iris/bitstream/10665/44602/1/9789241501613_eng. pdf?ua=1&ua=1 21

13 Should a positive skin test result be a requirement for administering IPT to people living with HIV? The WHO recommends that TST is not a requirement for administering IPT to people living with HIV. Symptom screening to exclude those with active TB should be the method used to administer IPT. 14 Do the 2011 WHO IPT ICF Guidelines recommend Interferon Gamma Release Assay (IGRA) for the screening of people living with HIV for IPT? IGRA35 is a test used which diagnoses latent TB in BCG vaccinated individuals, using blood samples. It is a more sensitive test than TST to diagnose latent TB in BCG vaccinated people. The TB specific antigens in the test activate the release of Interferon Gamma from the blood of a person who is infected with TB. 33 IGRA tests cannot distinguish between latent infection and active TB disease and should not be used for diagnosis of active TB, as was the case in India, until the Government banned it for use for the false diagnosis of active TB. 34 IGRA tests are not recommended by WHO for the screening of children and adults living with HIV for IPT, since IGRAs cannot accurately predict the risk of infected individuals developing active TB disease. IGRAs are more costly and technically complex to do than the TST 35 Significantly higher rates (11.5% vs 4.3%) of indeterminate test results were found in persons with HIV compared to persons without HIV, and in persons with low CD4 cell counts compared to persons with higher CD4 cell counts. 36 34 Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resourceconstrained settings, 2011, World Health Organisation, Geneva, Switzerland. Available at http://whqlibdoc.who.int publications/2011/9789241500708_eng.pdf. 35 Also marketed as QuantiFERON Gold- TB Gold or TB platinum 36 Fact Sheet, Testing for Tuberculosis (TB), 2011, Centers for Disease Control and Prevention (CDC), Available at http://www. cdc.gov/tb/publications/factsheets/testing/tb_factsheet.pdf 22